API
< Back to all clusters
[BUSINESS] · Germany · 3 sources

started · updated

Fresenius shares rise following new development agreement

Fresenius shares rose by up to three percent on Monday, leading the DAX after the company announced a development agreement with WuXi Biologics. The partnership focuses on biosimilar candidates, potentially expanding the company’s portfolio from 29 to 66 molecules over the next decade.

While the agreement is expected to increase research and development expenses in the short term, it is intended to drive long-term revenue and profit growth. Fresenius will retain full economic product rights and fund the initiative through operational cash flow without impacting debt reduction efforts.

Separately, Fresenius Medical Care reported third-quarter results that, while impacted by rising personnel costs and restructuring in China, exceeded analyst expectations. The company issued a revised 2026 outlook, projecting that adjusted operating results will remain stable or decline by a mid-single-digit percentage when adjusted for currency.

Entities

DAX · Fresenius · Fresenius Medical Care · Shervin Korangy · WuXi Biologics